title: Venous thromboembolism following total knee replacement.
abstract: Venous thromboembolic disease (VTE) remains the most common and potentially fatal complication following total knee replacement (TKR). Its incidence has been reported in excess of 50% if no prophylaxis is used. Even with current prophylaxis regimens, VTE incidence remains high in the range of 25% to 30%. Three prophylaxis regimens are recommended according to the guidelines put forth by the American College of Chest Physicians: 1) low-molecular-weight heparin, 2) indirect factor Xa inhibitor, and 3) adjusted-dose warfarin. Phase II and III clinical trials are currently underway to evaluate the efficacy and safety of newer antithrombotic agents as prophylaxis against VTE following TKR.
authors: Department of Orthopaedic Surgery, UT Southwestern Medical Center, Dallas, TX 75390-8883, USA.
authors: Bryan Y
authors: BY
authors: Choi
authors: Michael H
authors: MH
authors: Huo
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D048228:Intermittent Pneumatic Compression Devices; D013923:Thromboembolism / Q000209:etiology* / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin